Literature DB >> 12197881

Temporary restoration of immune response against Toxoplasma gondii in HIV-infected individuals after HAART, as studied in the hu-PBMC-SCID mouse model.

M Alfonzo1, D Blanc, C Troadec, M Huerre, M Eliaszewicz, G Gónzalez, Y Koyanagi, D Scott-Algara.   

Abstract

We studied immune reconstitution against the parasite T. gondii in HIV-infected patients treated for 1 years with highly active antiretroviral therapy (HAART). We used SCID mice, humanized with peripheral blood mononuclear cells (PBMC) from patients, which were then infected with T. gondii cysts. Mice humanized with PBMC from patients before the start of HAART were highly susceptible to infection. In contrast, mice humanized with PBMC from patients who had received HAART for 6 months displayed higher survival rates, correlating with lower intracerebral parasite loads. However, this resistance was lost during follow up because mice humanized with PBMC from patients treated with HAART for 12 months survived for no longer than mice that had not been humanized. Specific lymphocyte proliferation assays showed that the increase in proliferative response depended on treatment duration and that HAART induced changes in IFN-gamma secretion in the presence of Toxoplasma antigens. Thus, our results indicate partial immune reconstitution against T. gondii in HIV-infected patients following HAART, possibly due to changes in the patterns of specific IFN-gamma production and redistribution of functional memory CD4+ cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12197881      PMCID: PMC1906477          DOI: 10.1046/j.1365-2249.2002.01941.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

1.  Human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo.

Authors:  T C Greenough; D B Brettler; M Somasundaran; D L Panicali; J L Sullivan
Journal:  J Infect Dis       Date:  1997-07       Impact factor: 5.226

2.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.

Authors:  B Autran; G Carcelain; T S Li; C Blanc; D Mathez; R Tubiana; C Katlama; P Debré; J Leibowitch
Journal:  Science       Date:  1997-07-04       Impact factor: 47.728

Review 3.  Immunopathogenesis of HIV infection.

Authors:  G Pantaleo; A S Fauci
Journal:  Annu Rev Microbiol       Date:  1996       Impact factor: 15.500

4.  Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy.

Authors:  M A Jacobson; M Zegans; P R Pavan; J J O'Donnell; F Sattler; N Rao; S Owens; R Pollard
Journal:  Lancet       Date:  1997-05-17       Impact factor: 79.321

5.  Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial Group.

Authors:  S Pueyo; L R Salmi; G Chêne; C Leport; P Morlat; L Dequae; V Grégoire; R Hafner; J L Vildé; B J Luft; J Aubertin; R Salamon
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1997-04-15

6.  HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies.

Authors:  M Connors; J A Kovacs; S Krevat; J C Gea-Banacloche; M C Sneller; M Flanigan; J A Metcalf; R E Walker; J Falloon; M Baseler; I Feuerstein; H Masur; H C Lane
Journal:  Nat Med       Date:  1997-05       Impact factor: 53.440

7.  IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice.

Authors:  I A Khan; L H Kasper
Journal:  J Immunol       Date:  1996-09-01       Impact factor: 5.422

8.  HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia.

Authors:  T Wendland; H Furrer; P L Vernazza; K Frutig; A Christen; L Matter; R Malinverni; W J Pichler
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

9.  Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors:  A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal:  N Engl J Med       Date:  1996-04-18       Impact factor: 91.245

10.  In vitro T cell function, delayed-type hypersensitivity skin testing, and CD4+ T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus.

Authors:  M J Dolan; M Clerici; S P Blatt; C W Hendrix; G P Melcher; R N Boswell; T M Freeman; W Ward; R Hensley; G M Shearer
Journal:  J Infect Dis       Date:  1995-07       Impact factor: 5.226

View more
  8 in total

1.  Rapid discovery of inhibitors of Toxoplasma gondii using hybrid structure-based computational approach.

Authors:  Sandhya Kortagere; Ernest Mui; Rima McLeod; William J Welsh
Journal:  J Comput Aided Mol Des       Date:  2011-02-26       Impact factor: 3.686

Review 2.  Importance of nonenteric protozoan infections in immunocompromised people.

Authors:  J L N Barratt; J Harkness; D Marriott; J T Ellis; D Stark
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 3.  Mice with human immune system components as in vivo models for infections with human pathogens.

Authors:  Patrick C Rämer; Obinna Chijioke; Sonja Meixlsperger; Carol S Leung; Christian Münz
Journal:  Immunol Cell Biol       Date:  2011-02-08       Impact factor: 5.126

4.  Latent toxoplasmosis is associated with neurocognitive impairment in young adults with and without chronic HIV infection.

Authors:  L Ene; T D Marcotte; A Umlauf; C Grancea; A Temereanca; A Bharti; C L Achim; S Letendre; S M Ruta
Journal:  J Neuroimmunol       Date:  2016-08-04       Impact factor: 3.478

5.  Host response profile of human brain proteome in toxoplasma encephalitis co-infected with HIV.

Authors:  Apeksha Sahu; Satwant Kumar; Sreelakshmi K Sreenivasamurthy; Lakshmi Dhevi N Selvan; Anil K Madugundu; Soujanya D Yelamanchi; Vinuth N Puttamallesh; Gourav Dey; Abhijith K Anil; Anand Srinivasan; Kanchan K Mukherjee; Harsha Gowda; Parthasarathy Satishchandra; Anita Mahadevan; Akhilesh Pandey; Thottethodi Subrahmanya Keshava Prasad; Susarla Krishna Shankar
Journal:  Clin Proteomics       Date:  2014-11-01       Impact factor: 3.988

Review 6.  An Overview of Peripheral Blood Mononuclear Cells as a Model for Immunological Research of Toxoplasma gondii and Other Apicomplexan Parasites.

Authors:  John Alejandro Acosta Davila; Alejandro Hernandez De Los Rios
Journal:  Front Cell Infect Microbiol       Date:  2019-02-08       Impact factor: 5.293

7.  Adverse outcomes associated with the treatment of Toxoplasma infections.

Authors:  Ahmed M Shammaa; Thomas G Powell; Imaan Benmerzouga
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

Review 8.  The utilization of humanized mouse models for the study of human retroviral infections.

Authors:  Rachel Van Duyne; Caitlin Pedati; Irene Guendel; Lawrence Carpio; Kylene Kehn-Hall; Mohammed Saifuddin; Fatah Kashanchi
Journal:  Retrovirology       Date:  2009-08-12       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.